HYDROXYFLUTAMIDE Chemical Properties

Melting point:

125-130°C

Boiling point:

443.8±45.0 °C(Predicted)

Density 

1.472

storage temp. 

room temp

solubility 

DMSO: >10mg/mL

pka

12.87±0.70(Predicted)

form 

powder

color 

white to tan

Safety Information

Hazard Codes 

Xi

Risk Statements 

36/37/38

Safety Statements 

26-36/37/39

WGK Germany 

3

RTECS 

TX1466250

HS Code 

2924297099

HYDROXYFLUTAMIDE Usage And Synthesis

Description

2-hydroxy Flutamide is the major metabolite formed during the metabolism of the non-steroidal antiandrogen flutamide by cytochrome P450 (CYP) isoforms CYP1A2 and CYP3A4. Through competitive inhibition of the binding of testosterone to the nuclear androgen receptor (AR; IC₅₀ = ~300-900), 2-hydroxy flutamide blocks the expression of AR target genes and prevents androgen-dependent stabilization of the AR. Compared to flutamide, 2-hydroxy flutamide is a more potent antiandrogen in vivo, demonstrating a higher binding affinity for the AR (0.1% binding affinity relative to dihydrotestosterone) and, thus, is the predominant contributor to the therapeutic effects of flutamide in the treatment of prostate cancer.

Chemical Properties

HYDROXYFLUTAMIDE is Yellow-Brown Powder

Uses

HYDROXYFLUTAMIDE is used non-steroidal antagonist Flutamide. Shown to be an antianhydrogen.

Uses

The active metabolite of the widely used non-steroidal antagonist Flutamide (F598850). Shown to be an antianhydrogen.

Uses

Shown to be an antianhydrogen. The active metabolite of the widely used non-steroidal antagonist flutamide

Biochem/physiol Actions

Hydroxyflutamide plays a role in preventing the binding of 5α-dihydrotestosterone (DHT) and testosterone to the androgen receptors.

References

[1] kolvenbag g, furr b j a, blackledge g r p. receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity[j]. prostate cancer and prostatic diseases, 1998, 1: 307-314.
[2] heinlein c a, chang c. androgen receptor in prostate cancer[j]. endocrine reviews, 2004, 25(2): 276-308.
[3] shet m s, mcphaul m, fisher c w, et al. metabolism of the antiandrogenic drug (flutamide) by human cyp1a2[j]. drug metabolism and disposition, 1997, 25(11): 1298-1303.
[4] gao w, kim j, dalton j t. pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands[j]. pharmaceutical research, 2006, 23(8): 1641-1658.

HYDROXYFLUTAMIDE(52806-53-8)Related Product Information

• Flutamide
• Sildenafil
• 2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (2-HYDROXYFLUTAMIDE)
• HYDROXYFLUTAMIDE, [3H]-
• 2-(Trifluoromethyl)benzene-1,4-diamine
• 4-Nitro-3-trifluoromethyl aniline
• 2-Amino-5-acetamidobenzotrifluoride
• 2-METHYL-D3-N-(4-NITRO-3-TRIFLUOROMETHYLPHENYL)-2-TRIMETHYLSILYLOXY-PROPAMIDE-3,3,3-D3
• HYDROXYFLUTAMIDE
• Hydroxy FlutaMide-d6
• 4-ACETAMIDO-2-METHYLNITROBENZENE
• 4'-NITRO-3'-(TRIFLUOROMETHYL)ACETANILIDE
• N-(4-AMINO-3-METHYLPHENYL)PROPANAMIDE